



**For Healthy  
Joint Mobility**

**Capsugel®**

**Lonza**

**Consumer interest indicates growth opportunity**

**70%**

Of Millennials would likely take  
a joint health supplement if  
proven effective<sup>1</sup>

**72%**

Of Gen X would likely take a  
joint health supplement if  
proven effective<sup>1</sup>

**78%**

Of Boomers would likely take  
a joint health supplement if  
proven effective<sup>1</sup>

## Joint health market trends

- Total Joint Health Category totaled \$3.9 Billion in 2019
- The total category experienced a 9% CAGR over the past 5 years
- North American Joint Health Sales - \$835.7 Million in 2019

## Science-backed

Randomized, double-blind, placebo-controlled clinical studies show the joint health benefits of UC-II® undenatured type II collagen:

- Significantly increased knee extension in healthy adults compared to placebo<sup>2</sup>
- Significantly increased joint comfort and function compared to placebo and glucosamine + chondroitin in people with osteoarthritis<sup>3</sup>

## Market need: UC-II®

- Consumers across all age ranges are recognising that our ability to move freely requires healthy joints, which function smoothly and recover well after exercise
- An aging population and a rising demand for efficacious products opens up exciting possibilities for innovative joint health supplements
- UC-II® is backed by 3 published well designed clinical studies on healthy subjects for joint support

**UC-II® ingredient work in the immune system to support joint health in one, 40 mg dose.**

## UC-II® ingredient market advantage

- |  |   |   |  |
|--|---|---|--|
|  | 3 published, well designed clinical studies on healthy subjects       |  | Small, once-daily 40mg dose, suitable for combo formulas |
|  | Superior benefits compared to glucosamine + chondroitin               |  | FDA notified and published new dietary ingredients (NDI) |
|  | Self-affirmed GRAS status determined by a leading toxicological group |  | Sourced and manufactured in the United States            |

<sup>1</sup> 2018 NMI SORD Data

<sup>2</sup> Lugo JP, et al. *J Int Soc Sports Nutr.* 2013;10:48

<sup>3</sup> Lugo JP, et al. *Nutr. J.* 2016;15:14.

**UC-II® For Healthy Joint Mobility**

## Contacts:



For further information about the products:

Visit: [www.capsugel.com](http://www.capsugel.com)

Email: [solutions@lonza.com](mailto:solutions@lonza.com)

Call: 800 845 6973

Or contact your Lonza representative